HUP0103660A2 - Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid - Google Patents
Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acidInfo
- Publication number
- HUP0103660A2 HUP0103660A2 HU0103660A HUP0103660A HUP0103660A2 HU P0103660 A2 HUP0103660 A2 HU P0103660A2 HU 0103660 A HU0103660 A HU 0103660A HU P0103660 A HUP0103660 A HU P0103660A HU P0103660 A2 HUP0103660 A2 HU P0103660A2
- Authority
- HU
- Hungary
- Prior art keywords
- hyaluronic acid
- pharmaceutical formulation
- formulation containing
- microbial enzyme
- hyaluronate
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title abstract 2
- 108090000790 Enzymes Proteins 0.000 title abstract 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title 1
- 229920002674 hyaluronan Polymers 0.000 title 1
- 229960003160 hyaluronic acid Drugs 0.000 title 1
- 230000000813 microbial effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 3
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
- C12Y402/02001—Hyaluronate lyase (4.2.2.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A találmány tárgya gyógyászati készítmény, amely különösen injekcióskészítményként ateromatózisos lerakódásokra visszavezethetőérbetegségek kezelésére alkalmas. Az injekciós készítmény baktériumeredetű hialuronát-liánt, illetve a hialuronát-liánból előállítotthialuronát-bontó enzimfragmenst tartalmaz. Az utóbbi fragmens szinténa találmány tárgyát képezi. A fragmenst úgy állítják elő, hogy aholoenzimet fajlagosan bontó proteázzal kezelik. ÓThe subject of the invention is a medicinal preparation, which is particularly suitable as an injection preparation for the treatment of vascular diseases attributable to atheromatous deposits. The injection preparation contains hyaluronate-lyan of bacterial origin and a hyaluronate-decomposing enzyme fragment produced from hyaluronate-lyan. The latter fragment is also the subject of the invention. The fragment is produced by treating the aholoenzyme with a protease that specifically degrades it. HE
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1998160542 DE19860542A1 (en) | 1998-12-23 | 1998-12-23 | An enzyme fragment with hyaluronate lyase activity is derived from streptococci and used for medical applications |
| DE1998160541 DE19860541A1 (en) | 1998-12-23 | 1998-12-23 | Composition for the treatment of vascular disease comprises holozyme with hyaluronate lyase activity from microbial origin |
| PCT/DE1999/004108 WO2000039290A2 (en) | 1998-12-23 | 1999-12-22 | Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0103660A2 true HUP0103660A2 (en) | 2002-01-28 |
Family
ID=26051101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0103660A HUP0103660A2 (en) | 1998-12-23 | 1999-12-22 | Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1056839A1 (en) |
| JP (1) | JP2002533473A (en) |
| KR (1) | KR20010041235A (en) |
| AU (1) | AU3032400A (en) |
| CA (1) | CA2318356A1 (en) |
| DE (1) | DE19982882D2 (en) |
| HU (1) | HUP0103660A2 (en) |
| IL (1) | IL138051A0 (en) |
| PL (1) | PL344745A1 (en) |
| WO (1) | WO2000039290A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19963538A1 (en) * | 1999-12-22 | 2001-07-05 | Univ Schiller Jena | Use of an enzyme to improve tissue absorption of drugs |
| DE10103271A1 (en) * | 2001-01-23 | 2002-07-25 | Knoell Hans Forschung Ev | Pharmaceutical formulation containing hyaluronatlyase, useful for softening of connective tissue in medical and cosmetic treatment, especially in shape correction |
| DK2177620T3 (en) | 2003-03-05 | 2015-01-26 | Halozyme Inc | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, use and pharmaceutical compositions comprising thereof |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| AU2003239763A1 (en) * | 2003-05-27 | 2005-01-04 | Friedrich-Schiller- Universität Jena | Hyaluronate lyase-containing agent for treating acute myocardial infarction or symptoms thereof and for the treatment of postinfarction myocarditis and myocardial ischaemia |
| DE102007031417A1 (en) | 2007-07-04 | 2009-01-08 | Friedrich-Schiller-Universität Jena | Hyaluronate lyase with a histidine tag e.g. useful in pharmaceutical formulations and medical products |
| RU2501811C2 (en) | 2007-11-13 | 2013-12-20 | Био-Текнолоджи Дженерал (Изрейел) Лтд. | Method for sterilisation by filtration of diluted viscoelastic biopolymers (versions) |
| WO2010077297A1 (en) | 2008-12-09 | 2010-07-08 | Halozyme, Inc. | Extended soluble ph20 polypeptides and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1120298A (en) * | 1966-07-11 | 1968-07-17 | Biorex Laboratories Ltd | Stabilised enzymes |
| US3708575A (en) * | 1970-05-13 | 1973-01-02 | Biorex Laboratories Ltd | Method for the treatment of atherosclerosis employing glucuronoglycos-aminoglycan-hyaluronate-lyase |
| US3728223A (en) * | 1971-10-08 | 1973-04-17 | Amano Pharma Co Ltd | Production of hyaluronidase from a strain of streptomyces |
| ATE245452T1 (en) * | 1998-12-23 | 2003-08-15 | Esparma Gmbh | HYALURONATE LYASE AS A PENETRATION PROMOTER IN TOPICAL AGENTS |
-
1999
- 1999-12-22 PL PL99344745A patent/PL344745A1/en not_active Application Discontinuation
- 1999-12-22 AU AU30324/00A patent/AU3032400A/en not_active Abandoned
- 1999-12-22 KR KR1020007009327A patent/KR20010041235A/en not_active Application Discontinuation
- 1999-12-22 WO PCT/DE1999/004108 patent/WO2000039290A2/en not_active Application Discontinuation
- 1999-12-22 DE DE19982882T patent/DE19982882D2/en not_active Expired - Lifetime
- 1999-12-22 IL IL13805199A patent/IL138051A0/en unknown
- 1999-12-22 HU HU0103660A patent/HUP0103660A2/en unknown
- 1999-12-22 CA CA002318356A patent/CA2318356A1/en not_active Abandoned
- 1999-12-22 EP EP99964464A patent/EP1056839A1/en not_active Withdrawn
- 1999-12-22 JP JP2000591182A patent/JP2002533473A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000039290A2 (en) | 2000-07-06 |
| EP1056839A1 (en) | 2000-12-06 |
| PL344745A1 (en) | 2001-11-19 |
| AU3032400A (en) | 2000-07-31 |
| DE19982882D2 (en) | 2001-10-04 |
| IL138051A0 (en) | 2001-10-31 |
| JP2002533473A (en) | 2002-10-08 |
| KR20010041235A (en) | 2001-05-15 |
| CA2318356A1 (en) | 2000-07-06 |
| WO2000039290A8 (en) | 2000-10-19 |
| WO2000039290A3 (en) | 2001-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1562897A4 (en) | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease | |
| MXPA02012272A (en) | Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv. | |
| DE60225556D1 (en) | DPP-IV INHIBITING PURINE DERIVATIVE FOR THE TREATMENT OF DIABETES | |
| NO20014507L (en) | Medication for the treatment of diabetes | |
| MXPA05006359A (en) | Disease treatment via antimicrobial peptide inhibitors. | |
| BR0313371A (en) | Compound, use of a compound and disease treatment method | |
| ATE447574T1 (en) | 3-AMINO-4-PHENYLBUTANIC ACID DERIVATIVES AS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | |
| DE60330485D1 (en) | FOR THE TREATMENT OF DIABETES | |
| DE60236413D1 (en) | INHIBITORS OF HMGB1 FOR THE TREATMENT OF TISSUE DISEASES | |
| EP1841426A4 (en) | Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease | |
| DE69433901D1 (en) | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING AND PROPHYLAXIS OF BACTERIAL INFECTIONS | |
| IN2005KO00312A (en) | ||
| HK1086186A1 (en) | Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain | |
| TW200505418A (en) | Phenacyl 2-hydroxy-3-diaminoalkanes | |
| ZA986593B (en) | A method for the treatment of staphylococcal disease | |
| ATE390928T1 (en) | COMPOSITIONS FOR TREATING SKIN DISEASES | |
| BR0015698A (en) | Compositions and methods for treating allergic diseases | |
| DE60033649D1 (en) | COMPOUNDS AND THERAPEUTIC METHODS | |
| DE602004017871D1 (en) | PREPARATIONS FOR THE TREATMENT OF ARTHRITICAL APPEARANCE | |
| HUP0103660A2 (en) | Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid | |
| ATE385807T1 (en) | PHARMACEUTICAL COMPOUND AND METHODS FOR TREATING HUMAN CARCINOMA USING ARGININE WITHDRAWAL | |
| MXPA03011466A (en) | Macrocycles useful in the treatment of alzheimer's disease. | |
| ATE516027T1 (en) | ORAZAMID OROTAT TO PREVENT LIVER DAMAGE | |
| NO955258L (en) | Medical use of enzymes | |
| EA200601238A1 (en) | MEDICATIONS FOR PREVENTION AND TREATMENT OF BROMIDROSIS AND TO IMPROVE THE ODOR OF THE BODY |